SEARCH RESULT

Total Matching Records found : 681

In the ‘pharmacy of the world’ -PT Jyothi Datta

-The Hindu Business Line From maker of versions of drugs, India's pharmaceutical industry has turned a top innovator Twenty years ago, Ranbaxy was a home-spun drug-maker. The Indian Patents Act allowed companies to make chemically-similar versions of innovative drugs. Visionaries in the pharmaceutical sector, like Parvinder Singh (Ranbaxy's key architect and member of its promoter family) and Anji Reddy (founder of Dr Reddy's Laboratories), were alive. And the pharmaceutical industry did not have...

More »

The Larger Implications of the Novartis Glivec Judgment-Sudip Chaudhuri

-Economic and Political Weekly The Supreme Court judgment on the Novartis-Glivec case is remarkable because it has gone beyond the specific technical and legal issues surrounding patents and has put the matter in a much larger political and economic perspective. The deeper implication of the judgment is that it is not only justified to deny patents when incremental innovation is trivial as in the Glivec case. The judgment has linked the...

More »

The aadhaar of mass Health insurance -Alok Agarwal

-The Hindu Business Line     Technology has improved the poor's access to healthcare. India grapples with the issue of a major divide between the well-to-do and the lower end of the population strata. The challenge of uplifting the ‘below the poverty line' section of the population remains a challenging task. One of the areas which ranks high on this priority list is access to healthcare facilities. As is well known, events related to emergency...

More »

Social Justice

KEY TRENDS   • According to National Sample Survey report no. 583: Persons with Disabilities in India, the percentage of persons with disability who received aid/help from Government was 21.8 percent, 1.8 percent received aid/help from organisation other than Government and another 76.4 percent did not receive aid/ help *8   • As per National Family Health Survey-4 (NFHS-4), the Under-five Mortality Rate (U5MR) was 57.2 per 1,000 live births (for the non-STs it was 38.5)...

More »

SC’s Novartis judgement renews focus on accessible medicine

The recent Supreme Court judgment dismissing pharma giant Novartis’ claim for patent protections in India for its award-winning and prohibitively priced anti-leukemia drug Glivec has renewed the focus on accessibly-priced drugs – in particular the failure of the Indian public healthcare system and health policy to ensure affordable drugs for all. Studies show that as much as 70% of health spending in India comes from out-of-pocket payments, with 50-80% of...

More »

Video Archives

Archives

share on Facebook
Twitter
RSS
Feedback
Read Later

Contact Form

Please enter security code
      Close